A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma""
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
NanoCarrier Co., Ltd.
Start Date
May 19, 2017
End Date
September 30, 2022
Administered By
Duke Cancer Institute
Awarded By
NanoCarrier Co., Ltd.
Start Date
May 19, 2017
End Date
September 30, 2022